^
    2d
    Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). (PubMed, Cancer Innov)
    Currently, PARP inhibitors such as Olaparib and Fluzoparib have been approved for clinical use. This consensus, based on the latest evidence-based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • AiRuiYi (fluzoparib)
    9d
    Fuzuloparib enhances radiosensitivity of gain-of-function mutant p53 R273H NSCLC by promoting SLC7A11/GSH/GPX4 axis mediated ferroptosis. (PubMed, NPJ Precis Oncol)
    Whether mutant p53 R273H-mediated radioresistance is related to the interaction between mutant p53 R273H and PARP1, and if PARP1 inhibitors (PARPi) can increase the radiosensitivity of mutant p53 R273H-expressing tumors have not been explored. Through in vitro and in vivo experiments, we determined that mutant p53 R273H promotes radioresistance in NSCLC by partially inhibiting ferroptosis through the SLC7A11/GSH/GPX4 axis, independently of PARP1, whereas FZ counteracts this effect by partially blocking the same axis to promote ferroptosis, presenting a potential novel strategy for treating NSCLC patients with gain-of-function mutant p53 R273H.
    Journal • PARP Biomarker
    |
    TP53 (Tumor protein P53) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    TP53 mutation
    |
    AiRuiYi (fluzoparib)
    13d
    FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
    |
    Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Idafang (ivonescimab) • bulumtatug fuvedotin (9MW2821) • AiRuiLi (adebrelimab) • IBI-354 • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
    16d
    PARP inhibitors in the treatment of ovarian cancer: a narrative review. (PubMed, Transl Cancer Res)
    It details the efficacy of major PARPis (olaparib, niraparib, rucaparib, and fuzuloparib) in pivotal trials. Overcoming resistance requires a multipronged approach integrating deep molecular profiling, mechanism-informed combination therapies, and biomarker-driven clinical trial designs. Future progress hinges on translating biological insights into personalized treatment strategies to extend durable remission for a greater portion of patients, while also addressing the economic and ethical implications of long-term maintenance therapy.
    Review • Journal • PARP Biomarker • IO biomarker
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib) • AiRuiYi (fluzoparib)
    1m
    Expert consensus on the clinical application of PARP inhibitors in breast cancer (2025 edition) (PubMed, Zhonghua Zhong Liu Za Zhi)
    Currently, PARP inhibitors such as olaparib and fluzoparib have been approved for clinical use. Based on the latest evidence-based medical data, the Professional Committee on Clinical Research of Oncology Drugs, China Anti-Cancer Association, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs and Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center have jointly organized and invited domestic oncology experts with rich diagnosis and treatment experience as well as relevant interdisciplinary experts to compile the "Expert consensus on the clinical application of PARP inhibitors in breast cancer (2025 edition)". This consensus aims to provide guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, with the goal of supporting clinical practice.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • AiRuiYi (fluzoparib)
    2ms
    A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=28, Completed, Xijing Hospital | Recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • ER positive • BRCA1 mutation • HER-2 negative • HRD • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    docetaxel • cyclophosphamide • AiRuiYi (fluzoparib)
    2ms
    A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor (clinicaltrials.gov)
    P=N/A, N=5, Terminated, Peking Union Medical College Hospital | N=70 --> 5 | Trial completion date: Oct 2028 --> Mar 2026 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2027 --> Mar 2026; Results failed to achieve the anticipated effect.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Platinum sensitive
    |
    ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    AiTan (rivoceranib) • letrozole • AiRuiYi (fluzoparib)
    3ms
    Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=80, Suspended, wang shusen | Trial completion date: Dec 2026 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)
    3ms
    Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib (clinicaltrials.gov)
    P2, N=48, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    carboplatin • paclitaxel • AiTan (rivoceranib) • AiRuiYi (fluzoparib)
    3ms
    A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, Xijing Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • ER positive • BRCA1 mutation • HER-2 negative • HRD • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    docetaxel • cyclophosphamide • AiRuiYi (fluzoparib)